| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 0 | 34.906 | 41.380 | 50.648 | 56.978 | 51.748 | 60.046 | 73.155 | 81.824 |
| Total Income - EUR | - | 0 | 34.906 | 41.380 | 50.648 | 59.046 | 51.749 | 60.047 | 73.156 | 81.826 |
| Total Expenses - EUR | - | 1.338 | 21.006 | 24.715 | 26.117 | 40.658 | 31.712 | 37.729 | 47.165 | 73.277 |
| Gross Profit/Loss - EUR | - | -1.338 | 13.900 | 16.665 | 24.531 | 18.388 | 20.037 | 22.318 | 25.990 | 8.549 |
| Net Profit/Loss - EUR | - | -1.338 | 13.551 | 16.251 | 24.025 | 17.857 | 19.501 | 21.729 | 25.207 | 6.462 |
| Employees | - | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Check the financial reports for the company - Ancudan Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 20.261 | 19.861 | 19.496 | 19.119 | 23.511 | 23.263 | 27.013 | 30.615 | 29.716 |
| Current Assets | - | 55 | 5.591 | 7.000 | 12.160 | 17.070 | 16.304 | 18.471 | 25.498 | 13.590 |
| Inventories | - | 0 | 0 | 0 | 20 | 536 | 524 | 0 | 0 | 442 |
| Receivables | - | 0 | 3.568 | 3.136 | 4.513 | 12.497 | 8.467 | 8.209 | 14.871 | 3.837 |
| Cash | - | 55 | 2.023 | 3.864 | 7.626 | 4.037 | 7.312 | 10.262 | 10.627 | 9.311 |
| Shareholders Funds | - | -1.294 | 12.279 | 17.023 | 25.230 | 31.754 | 33.571 | 23.466 | 37.615 | 22.027 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 21.609 | 13.172 | 9.473 | 6.049 | 8.827 | 5.996 | 22.049 | 18.497 | 21.318 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8621 - 8621" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - Ancudan Med Srl